According to the latest industry analysis by Future Market Insights, the global cervical cancer screening market is expected to surge from US$ 1.6 billion in 2023 to an estimated US$ 5.7 billion by 2033, expanding at a compound annual growth rate (CAGR) of 13.7%. This growth trajectory is primarily driven by the increased incidence of cervical cancer and significant advancements in screening technologies.
Cervical cancer has been noted for its significant increase in new and existing cases. A report by the American Society of Clinical Oncology in 2020 highlighted a 20% rise in cervical cancer patients compared to pre-pandemic figures, the highest among the five common cancers examined. This spike underscores the critical need for effective screening and early detection strategies, which can significantly diminish the disease’s impact through timely intervention.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-17206
Preventative measures, such as vaccination against high-risk human papillomavirus (HPV), alongside innovative screening and diagnostic techniques, play a pivotal role in combating the onset of cervical cancer. Effective management and treatment of pre-invasive lesions are crucial steps that can substantially reduce cancer incidence.
In light of the challenges posed by limited access to pathology services, especially in under-resourced regions like Africa, technological innovations are increasingly vital. A notable innovation in this area is the mobile health application iThemba Life, which equips users with crucial HPV viral load data, educational materials, and personalized reminders and support directly via their smartphones. This technology exemplifies the industry’s shift towards patient-centric solutions that not only facilitate early detection but also enhance patient engagement and management of their health.
The global demand for cervical cancer screening solutions is expected to remain robust, propelled by a continuous need for innovative and effective health management technologies. As industry stakeholders continue to invest in and develop advanced screening methodologies, the market is poised to maintain a dynamic growth pace, offering new opportunities for the prevention and early detection of cervical cancer worldwide.
For detailed insights on enhancing your product footprint, along with analytics and market forecasts, contact Future Market Insights. Together, we can transform challenges into opportunities by ensuring better health outcomes and accessibility for all women, particularly those in underserved regions.
Key Takeaways:
- Human papillomavirus (HPV) is the leading segment of tests among end users and held about 75.0% market share in 2022, for risk stratification, HPV testing offers useful information. HPV comes in a variety of forms, including high- and low-risk varieties. While low-risk HPV variants typically result in benign genital warts, high-risk HPV strains are linked to an elevated risk of cervical cancer.
- By cancer, squamous cell carcinomas are the predominant type and are significantly linked to high-risk HPV infections, particularly those caused by HPV types 16 and 18.
- 31 to 65 years held the maximum market share of 61.7%, the age range of 31 to 65 years includes a time when people’s rate of cumulative exposure to HPV has become high.
- Hospital segment by end user accounted for a revenue share of 39.7% in the global market at the end of 2022. Hospitals often have advanced diagnostic facilities and equipment, including imaging technologies, pathology laboratories, and access to specialized tests. These resources can support a comprehensive diagnostic workup and aid in reaching an accurate diagnosis.
- By region, North America is leading in the global Cervical Cancer Screening market and is expected to continue to do so with a projected CAGR rate of 12.6% during the forecasted years.
“Increasing adoption of screening for the identification of cervical cancer, advancements in detection and management for improved outcomes are the key drivers of the Cervical Cancer Screening market,” says an analyst at Future Market Insights (FMI).
Methodology Details Just a Click Away: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17206
Market Competition:
In their pursuit of market expansion, key players in the Cervical Cancer Screening industry are employing growth strategies such as acquisitions, mergers, collaborations, and partnerships. These companies prioritize enhancing sales efforts and leveraging new technologies to develop innovative products.
- According to the new In-Vitro Diagnostic Medical Devices Regulation (IVDR) in Germany, which replaces the old IVDD requirements, QIAGEN announced in October 2022 that their top in-vitro diagnostic (IVD) kit and its fully automated NeuMoDx platforms have been certified.
- Everlywell a company that operates in Austin considerably broadened its horizons in March 2021 with the aid of double acquisitions and a restructuring that involved the creation of a parent company, all directed by Everlywell CEO and co-founder Julia Cheek.
Key Players:
- Abbott Laboratories
- Becton, Dickinson, and Company
- F. Hoffmann-La Roche
- Hologic, Inc.
- QIAGEN
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- Promega Corporation
- Sysmex Inostics Inc.
- Danaher (Cepheid)
- FUJIREBIO
- Everlywell, Inc.
- Sansure Biotech Inc.
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the Cervical Cancer Screening market in its latest study, presenting a historical demand assessment of 2012 to 2022 and projections for 2023 to 2033. The global Cervical Cancer Screening market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
Request Purchase on Report: https://www.futuremarketinsights.com/checkout/17206
Key Segments Covered:
By Test:
- Cervical Cytology (Pap smear)
- Human Papillomavirus (HPV)
- Visual inspection with acetic acid (VIA)
By Cancer:
- Squamous Cell Carcinomas
- Adenocarcinomas
By Age Group:
- 21 to 30 Years
- 31 to 65 Years
By End User:
- Hospitals
- Cancer Research Institutes
- Specialty Clinics
- Diagnostic Laboratories
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
